Table 2.
Vaccine Effectiveness Against Pooled Estimates, Stratified by Sexual Activity When Vaccination Was Offered and Time Since Vaccination Was Offered
| VE (95%CI)a | ||||
|---|---|---|---|---|
| n (%) | HPV-16/18 | Hr nonavalent typesb | All hrHPVc | |
| Women not sexually active when vaccination was offered | ||||
| Unvaccinated | 303 (37.7) | |||
| Vaccinated (≥1 dose) | 501 (62.3) | 92.2 (83.2–96.4) | 60.1 (47.1–70.0) | 29.6 (13.4–42.7) |
| Women (possibly) sexually active when vaccination was offered d | ||||
| Unvaccinated | 119 (47.6) | |||
| Vaccinated (≥1 dose) | 131 (52.4) | 81.1 (52.1–92.5) | 60.2 (36.2–75.2) | 39.9 (16.3–56.8) |
| Women offered vaccination <5 years ago | ||||
| Unvaccinated | 178 (43.1) | |||
| Vaccinated (≥1 dose) | 235 (56.9) | 83.2 (57.9–93.3) | 50.7 (23.9–68.1) | 33.0 (10.4–49.8) |
| Women offered vaccination 5/6 years ago | ||||
| Unvaccinated | 244 (38.1) | |||
| Vaccinated (≥1 dose) | 397 (61.9) | 92.4 (83.6–96.5) | 65.5 (53.9–74.1) | 34.6 (19.0–47.2) |
Abbreviations: CI, confidence interval; HPV, human papillomavirus; hr, high-risk; VE, vaccine effectiveness.
VE was corrected for: ethnicity, education level, recent sex partners, age at sexual debut, history of sexually transmitted infections, hormonal contraceptives use, and age vaccination was offered.
Including HPV types HPV-16/18/31/33/45/52/58.
Including HPV types HPV-16/18/31/33/35/39/45/51/52/56/58/59.
Includes women who reported the same age (in years) of sexual debut as the age they were offered vaccination.
For the catch-up cohorts, vaccination was offered on 1 March 2009. For the cohorts vaccinated in the National Immunization Program, vaccination was offered on 1 March in the year they turned 13 years old.